Vasoactive intestinal peptide stimulates p59fyn kinase activity in murine thymocytes

Peptides

Volumn 18, Issue 8, 1997, Pages 1151-1159

  Xin, Zhicheng ^a,b   Sun, Lei ^a,c   Ganea, Doina ^a,d  

^a Dept of Biol SciencesRutgers Univ ^*  (United States)

^b RUTGERS UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

cAMP inducing agents; p56Lck; p59Fyn; Protein tyrosine kinases; Thymocytes; Vasoactive intestinal peptide

Indexed keywords

8 BROMO CYCLIC AMP; FORSKOLIN; PROSTAGLANDIN E2; PROTEIN TYROSINE KINASE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THYMOCYTE;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FYN; THYMUS GLAND; TYROSINE; VASOACTIVE INTESTINAL PEPTIDE;

ANIMALIA; MURINAE;

EID: 0031442572     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(97)00136-8     Document Type: Article

References (52)

1. Anastassiou E. D., Paliogianni F., Balow J. P., Yamada H., Boumpas D. T. PGE2 and other cAMP elevating agents modulate IL-2 and IL-2Rα gene expression at multiple levels. J. Immunol. 148:1992;2845-2852.
2. Anderson K. L., Anderson G., Mitchell R. H., Jenkinson E. J., Owen J. J. T. Intracellular signaling pathways involved in the induction of apoptosis in immature thymic T lymphocytes. J. Immunol. 156:1996;4083-4091.
3. Anderson S. J., Levin S. D., Perlmutter R. M. Involvement of protein tyrosine kinase p56lck in T cell signaling and thymocyte development. Adv. Immunol. 56:1994;151-177.
4. Appleby M. W., Gross J. A., Cooke M. P., Levin S. D., Qian X., Perlmutter R. M. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell. 70:1992;751-763.
5. Bellinger D. L., Lorton D., Brouxhon S., Felten S., Felten D. L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6:1996;5-27.
6. Betz M., Fox B. S. PGE2 inhibits production of TH1 but not TH2 lymphokines. J. Immunol. 146:1991;108-113.
7. Borod J., Spetz A. L., Strominger J. L., Habener J. F. cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc. Natl. Acad. Sci. USA. 93:1996;3536-3541.
8. Calvo J. R., Pozo D., Guerrero J. M. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv. Neuroimmunol. 6:1996;39-47.
9. Cohn J. A. Vasoactive intestinal peptide stimulates protein phosphorylation in a colonic epithelial cell line. Gastrointest. Liver Physiol. 16:1987;G420-G424.
10. Cooke M. P., Abraham K. M., Forbush K. A., Perlmutter R. M. Regulation of T cell receptor signaling by a src family protein-tyrosine kinase (p59fyn). Cell. 65:1991;281-291.
11. Da Silva A. J., Yamamoto M., Zalvan C. H., Rudd C. E. Engagement of the TCR/CD3 complex stimulates p59fyn(T) activity; detection of associated proteins at 72 and 120-130KD. Mol. Immunol. 29:1992;1417-1425.
12. Davidson D. L., Chow M. L., Fournel M., Veilette A. Differential regulation of T cell antigen responsiveness by isoforms of the src-related tyrosine protein kinase p59fyn. J. Exp. Med. 175:1992;1483-1492.
13. De la Fuente M., Delgado M., Gomariz R. P. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6:1996;75-94.
14. Delgado M., Garrido E., Martinez C., Leceta J., Gomariz R. P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis. Blood. 87:1996;5152-5161.
15. Delgado M., Martinez C., Johnson M., Gomariz R. P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) in murine lymphocytes. J. Neuroimmunol. 68:1996;27-38.
16. Erndstrom U., Gafvelin G., Mutt V. Rescue of thymocytes from cell death by vasoactive intestinal peptide. Regul. Pept. 57:1995;99-104.
17. Feder D., Bishop J. M. Purification and enzymatic characterization of pp60c-src from human platelets. J. Biol. Chem. 265:1990;8205-8211.
18. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:1996;61-74.
19. Ganea D., Sun L. VIP downregulates the expression of IL-2 but not of IFNγ from stimulated murine T lymphocytes. J. Neuroimmunol. 47:1993;147-158.
20. Gomariz R. P., Garrido E., Leceta J., Martinez C., Abalo R., Delgado M. Gene expression of VIP receptor in rat lymphocytes. Biochem. Biophys. Res. Commun. 203:1994;1599-1604.
21. Hsueh Y. P., Lai M. Z. C-jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T lymphocytes. J. Biol. Chem. 270:1995;18094-18098.
22. Johnson M., McCormack R., Delgado M., Martinez C., Ganea D. Murine T lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J. Neuroimmunol. 68:1996;109-119.
23. June C. H., Fletcher M. C., Ledbetter J. A., Samelson L. E. Increases in tyrosine phosphorylation are detectable before phopholipase C activation after T cell receptor stimulation. J. Immunol. 144:1990;1591-1599.
24. 2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFNγ and IL-2, but not IL-4 and IL-5. J. Immunol. 155:1995;4604-4612.
25. Kazanawa S., Ilic D., Hashiyama M., Noumura T., Yamamoto T., Suda T., Alzawa S. p59fyn-p125FAK cooperation in the development of CD4+CD8+ thymocytes. Blood. 87:1996;865-870.
26. Kimata H. Vasoactive intestinal peptide differentially modulates human immunoglobulin production. Adv. Neuroimmunol. 6:1996;107-115.
27. src. Biochem. Biophys. Res. Commun. 174:1991;452-458.
28. Lee H. J., Matsuda I., Naito Y., Yokota T., Arai N., Arai K. Signals and nuclear factors that regulate the expression of IL-4 and IL-5 genes in helper T cells. J. Allergy Clin. Immunol. 94:1994;594-601.
29. Martinez C., Delgado M., Gomariz R. P., Ganea D. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP38) inhibit IL10 production in murine T lymphocytes. J. Immunol. 156:1996;4128-4136.
30. Metwali A., Elliott D., Blum A. M., Li J., Sandor M., Weinstock J. V. T cell vasoactive intestinal peptide receptor subtype expression differs between granulomas and spleen of Schistosome-infected mice. J. Immunol. 157:1996;265-270.
31. Migita K., Eguchi K., Kawabe Y., Mizokami A., Tsukada T., Nagataki S. Prevention of anti-CD3 monoclonal antibody-induced thymic apoptosis by proteinase inhibitors. J. Immunol. 153:1994;3457-3465.
32. Molina T. J., Kishihara K., Siderovski D. P., Ewijk W. V., Narendran A., Timms E., Wakeham A., Paige C. J., Hartman K. U., Veilette A., Davidson D., Mak T. W. Profound block in thymocyte development in mice lacking p56lck. Nature. 257:1992;161-164.
33. Novak T. J., Rothenberg E. V. cAMP inhibits induction of IL-2 but not IL-4 in T cells. Proc. Natl. Acad. Sci. USA. 87:1990;9353-9358.
34. Okumura N., Miyataka Y., Takao T., Tamaru T., Nagai K., Okada M., Nakagawa H. Vasoactive intestinal peptide induces differentiation and MAP kinase activation in PC12h cells. J. Biochem. 115:1993;304-308.
35. Okumura N., Okada M., Nagai K., Nakagawa H. Vasoactive intestinal peptide induces tyrosine phosphorylation in PC12h cells. J. Biochem. 116:1994;341-345.
36. Olah Z., Lehel C., Anderson W. B., Brenneman D. E., VonAgoston D. Subnanomolar concentrations of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. J. Neurosci. Res. 39:1994;355-363.
37. Olszwy M. W., Leuchtmann P. L., Veillette A., Shaw A. S. Comparison of p56lck and p59fyn protein expression in thymocyte subsets, peripheral T cells, NK cells, and lymphoid cell lines. J. Immunol. 155:1995;4236-4240.
38. Paliogianni F., Kincaid R. L., Boumpas D. T. PGE2 and other cAMP elevating agents inhibit IL-2 gene transcription by counteracting calcineurin-dependent pathways. J. Exp. Med. 178:1993;1813-1818.
39. Robberecht P., Gourlet P., Vertongen P., Svoboda M. Characterization of the VIP receptor from SUP T1 lymphoblasts. Adv. Neuroimmunol. 6:1996;49-57.
40. Rudd C. E., Janssen O., Cai Y. C., Da Silva A. J., Raab M., Prasad K. V. S. Two-step TCRζ/CD3-CD4 and CD28 signaling in T cells SH2/SH3 domains, protein-tyrosine and lipid kinases . Immunol. Today. 15:1994;225-231.
41. Stein P. L., Lee H. M., Rich S., Soriano P. pp59fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell. 70:1992;741-750.
42. Straus D. B., Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell. 70:1992;585-593.
43. Sun L., Ganea D. VIP inhibits IL-2 and IL-4 production through different mechanisms in T cells activated via the TCR/CD3 complex. J. Neuroimmunol. 48:1993;59-70.
44. Tamura T., Nakano H., Nagase H., Morokata T., Igarashi O., Oshimi Y., Miyazaki S., Nariuchi H. Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti-CD3. J. Immunol. 155:1995;4692-4701.
45. Tang H., Sun D., Xin Z., Ganea D. Downregulation of cytokine expression by murine lymphocytes by PACAP and VIP. Ann. NY Acad. Sci. 805:1996;768-778.
46. Tang H., Welton A., Ganea D. Neuropeptide regulation of cytokine expression effects of VIP and Ro 25-1553 . J. Interferon Cytokine Res. 15:1995;993-1003.
47. Tsygankov A. Y., Broker B. M., Fargnoli J., Ledbetter J. A., Bolen J. B. Activation of tyrosine kinase p60fyn following T cell antigen receptor crosslinking. J. Biol. Chem. 267:1992;18259-18265.
48. Veillette A., Horak I. D., Horak E. M., Bookman M. A., Bolen J. B. Alterations of the lymphocyte-specific protein tyrosine kinase p56lck during T cell activation. Mol. Cell. Biol. 8:1988;4353-4361.
49. Wang H-Y., Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156:1996;3243-3253.
50. Washek J. A., Bravo D. T., Richards M. L. High levels of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide receptor mRNA expression in primary and tumor lymphoid cells. Regul. Pept. 60:1995;149-155.
51. Xin Z., Tang H., Ganea D. VIP inhibits IL-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J. Neuroimmunol. 54:1994;59-68.
52. Zorn N. E., Russell D. H. Vasoactive intestinal peptide activation of nuclear protein kinase C in purified nuclei of rat splenocytes. Biochem. Pharmacol. 40:1990;2689-2694.